https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-july-3-2026/ 2026-07-04T14:44:42Z Pharminent en GLP-1 Competitive Market Digest • Weekly • July 3, 2026 2026-07-04T14:44:40Z Blog https://pharminent.com/medicare-glp-1-bridge-launches-july-1-with-50-copays/ 2026-07-03T21:06:23Z Pharminent en Medicare GLP-1 Bridge Launches July 1 With $50 Copays 2026-07-03T20:46:53Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-july-3-2026/ 2026-07-03T19:32:11Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • July 3, 2026 2026-07-03T19:32:09Z Blog https://pharminent.com/biontech-held-buyer-talks-over-four-german-sites-set-to-close-handelsblatt-reports/ 2026-07-03T19:13:30Z Pharminent en BioNTech Held Buyer Talks Over Four German Sites Set to Close, Handelsblatt Reports 2026-07-03T19:13:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-3-2026/ 2026-07-03T18:35:48Z Pharminent en Strategic News Watch • July 3, 2026 2026-07-03T15:49:19Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-2-2026/ 2026-07-02T20:42:50Z Pharminent en Rare Disease & Gene Therapy Digest • July 2, 2026 2026-07-02T20:42:48Z Blog https://pharminent.com/roches-divarasib-beats-amgen-and-bms-head-to-head-in-phase-3-kras-lung-cancer-trial/ 2026-07-02T17:46:58Z Pharminent en Roche's Divarasib Beats Amgen and BMS Head-to-Head in Phase 3 KRAS Lung Cancer Trial 2026-07-02T17:46:58Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-2-2026/ 2026-07-02T16:15:11Z Pharminent en Strategic News Watch • July 2, 2026 2026-07-02T16:15:10Z Blog https://pharminent.com/biogen-bets-on-tau-at-aaic-diranersen-phase-2-celia-data/ 2026-07-02T14:23:25Z Pharminent en Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data 2026-07-02T14:23:25Z Blog https://pharminent.com/novartis-receives-european-commission-approval-for-itvisma-for-spinal-muscular-atrophy/ 2026-07-03T14:05:48Z Pharminent en Novartis receives European Commission approval for Itvisma for spinal muscular atrophy 2026-07-02T13:32:11Z Blog https://pharminent.com/az-forges-ever-closer-ties-with-chinas-cspc-pharma/ 2026-07-03T14:06:19Z Pharminent en AZ forges ever-closer ties with China's CSPC Pharma 2026-07-02T11:59:18Z Blog https://pharminent.com/roches-kras-drug-tops-its-rivals-in-lung-cancer-trial/ 2026-07-02T17:22:00Z Pharminent en Roche's KRAS drug tops its rivals in lung cancer trial 2026-07-02T10:11:25Z Blog https://pharminent.com/insilico-medicine-takeda-partner-on-ai-driven-drug-discovery/ 2026-07-03T14:07:43Z Pharminent en Insilico Medicine, Takeda partner on AI-driven drug discovery 2026-07-02T09:57:47Z Blog